April 07, 2026

Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer

As reported in The New England Journal of Medicine by Vulsteke et al, the phase III KEYNOTE-905/EV-303 trial has shown improved event-free and overall survival with the addition of perioperative enfor...

The ASCO Post

April 07, 2026

Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer

The combination of the NECTIN4-directed antibody drug conjugate enfortumab vedotin-ejfv and the immunotherapy drug pembrolizumab is the established first-line standard-of-care treatment for patients w...

The ASCO Post

April 06, 2026

Tanning Bed Exposure and Melanoma Risks

Research has elucidated how radiation from tanning beds increases the mutation burden across a broad area of melanocytes, thereby significantly raising the risk of developing melanoma. Findings publis...

The ASCO Post

April 06, 2026

AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation

In a systematic review and meta-analysis published in JAMA Dermatology, Laiouar-Pedari et al evaluated the real-world diagnostic performance of artificial intelligence (AI)–assisted dermoscopy for mel...

The ASCO Post

April 03, 2026

HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer

The addition of the selective HER2 inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly prolonged investigator-assessed progression-free survival in patien...

The ASCO Post

April 02, 2026

Financial Hardship and Late-Stage Cancer Diagnosis

In a study reported in the Journal of Clinical Oncology, Khor et al found that prediagnosis financial hardship was associated with a diagnosis of cancer at later stages, particularly for cancers with ...

The ASCO Post

April 01, 2026

Activity Observed With Novel KRAS Inhibitor in Pancreatic Cancer

A novel KRAS G12D inhibitor produced disease control in almost 80% of patients with heavily pretreated advanced or metastatic KRAS G12D–mutated pancreatic cancer in an early-phase study reported at th...

The ASCO Post

April 01, 2026

Early Results From a Trial of Active Surveillance for Low-Risk DCIS are ‘Reassuring,’ Say Researchers

“For women with low-risk DCIS, these interim results are reassuring. There is currently no indication that active surveillance leads to worse early outcomes compared with immediate surgery. It’s impor...

The ASCO Post

March 31, 2026

Molecular Test Doubles Detection of Bile Duct Cancer

According to recent research, a new molecular test could detect bile duct cancer with twice the sensitivity of the standard test, giving physicians a more accurate picture of a patient’s diagnosis. 

The ASCO Post

March 31, 2026

Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence

“Adjuvant pembrolizumab plus belzutifan demonstrated a statistically significant and clinically meaningful improvement in disease-free survival vs pembrolizumab plus placebo in patients with clear cel...

The ASCO Post